PharVision Advisers LLC Invests $201,000 in Alphatec Holdings, Inc. (NASDAQ:ATEC)

PharVision Advisers LLC bought a new position in Alphatec Holdings, Inc. (NASDAQ:ATEC - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 21,895 shares of the medical technology company's stock, valued at approximately $201,000.

A number of other large investors also recently modified their holdings of ATEC. Lido Advisors LLC lifted its stake in Alphatec by 8.4% during the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company's stock valued at $112,000 after acquiring an additional 953 shares in the last quarter. PNC Financial Services Group Inc. lifted its stake in Alphatec by 0.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company's stock valued at $2,873,000 after acquiring an additional 1,120 shares in the last quarter. Comerica Bank lifted its stake in Alphatec by 66.8% during the 4th quarter. Comerica Bank now owns 3,116 shares of the medical technology company's stock valued at $29,000 after acquiring an additional 1,248 shares in the last quarter. Summit Investment Advisors Inc. lifted its stake in Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company's stock valued at $100,000 after acquiring an additional 1,342 shares in the last quarter. Finally, Rhumbline Advisers lifted its stake in Alphatec by 1.3% during the 4th quarter. Rhumbline Advisers now owns 139,088 shares of the medical technology company's stock valued at $1,277,000 after acquiring an additional 1,746 shares in the last quarter. 66.35% of the stock is currently owned by institutional investors.

Alphatec Stock Performance

ATEC traded down $0.13 during trading hours on Tuesday, hitting $12.32. The stock had a trading volume of 1,661,643 shares, compared to its average volume of 2,040,500. The company's fifty day simple moving average is $11.11 and its 200 day simple moving average is $10.57. Alphatec Holdings, Inc. has a 1 year low of $4.88 and a 1 year high of $13.14. The stock has a market cap of $1.80 billion, a PE ratio of -9.63 and a beta of 1.06. The company has a quick ratio of 1.15, a current ratio of 2.32 and a debt-to-equity ratio of 30.21.

Alphatec (NASDAQ:ATEC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. The firm had revenue of $169.18 million during the quarter, compared to analysts' expectations of $167.57 million. During the same period last year, the business posted ($0.34) EPS. The company's revenue was up 22.2% compared to the same quarter last year. Equities analysts anticipate that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the company. HC Wainwright reiterated a "buy" rating and set a $20.00 target price on shares of Alphatec in a research note on Monday, April 14th. Wall Street Zen upgraded Alphatec from a "sell" rating to a "hold" rating in a research note on Friday, February 28th. Piper Sandler reiterated an "overweight" rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. Finally, Needham & Company LLC reiterated a "buy" rating and set a $16.00 target price on shares of Alphatec in a research note on Friday, May 2nd. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and an average target price of $17.89.

Insider Buying and Selling

In other Alphatec news, CEO Patrick Miles sold 12,691 shares of Alphatec stock in a transaction dated Friday, March 7th. The stock was sold at an average price of $10.64, for a total transaction of $135,032.24. Following the completion of the transaction, the chief executive officer now owns 5,857,603 shares of the company's stock, valued at $62,324,895.92. The trade was a 0.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, COO Scott Lish sold 12,000 shares of Alphatec stock in a transaction dated Monday, May 5th. The shares were sold at an average price of $12.12, for a total value of $145,440.00. Following the transaction, the chief operating officer now directly owns 826,251 shares of the company's stock, valued at $10,014,162.12. The trade was a 1.43% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 169,374 shares of company stock valued at $1,997,316. 20.90% of the stock is owned by insiders.

About Alphatec

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.